Poor glycemic control in type-2 diabetic patients infected with hepatitis B: a retrospective propensity-matched study.

Hepatitis B virus (HBV) infection and type-2 diabetes (T2DM) affect millions of individuals worldwide, whereas their interplay remains largely unclear. Here, we analyzed a large cohort of 330 HBV-infected inpatients with T2DM (so-called HBV+T2DM patients) and 330 T2DM inpatients without HBV infection (T2DM patients). Poor glycemic control was defined by glycated hemoglobin (HbA1c) ≥7%. Among 330 HBV+T2DM patients, 252(76%) aged ≥50 years, 223(68%) were males, 205(62%) experienced poor glycemic control. The propensity-score matching approach was applied to match patient age, gender, comorbidities, and antidiabetic treatment between T2DM+HBV and T2DM patients. Compared with T2DM patients, HBV+T2DM patients had poorer glycemic control, longer hospitalization length, and higher alanine aminotransferase (p-values<0.05). HBV+T2DM patients with HBV DNA≥100 IU/mL or HBsAg ≥0.05 IU/mL had worse HbA1c control than T2DM patients without HBV infection (p-values<0.05). HBV+T2DM patients who received no anti-HBV therapy had worse HbA1c control than HBV+T2DM patients receiving anti-HBV therapy (p-value<0.05). Both insulin and anti-HBV therapy were significant factors associated with glycemic control in HBV+T2DM patients. Overall, HBV+T2DM patients exhibited poorer glycemic control than T2DM patients, but their clinical outcomes were likely improved by insulin plus anti-HBV treatment. Early management of HBV infection likely contributes to better clinical outcomes in HBV-infected patients with T2DM. This article is protected by copyright. All rights reserved.